ABOUT PARKINSON'S DISEASE RISK

Your hand trembles — and you're wondering if it's the same disease your parent lived with. Knowing your genetics could unlock a treatment they never had.

Whole genome sequencing identifies monogenic Parkinson's variants and polygenic risk factors, connecting you to precision medicine trials and targeted therapies that didn't exist a generation ago.

CLIA CertifiedCAP AccreditedISO 15189 Medical LabACMG ClassifiedHIPAA & GDPR100,000+ Genomes Sequenced

About this condition

Parkinson's Disease Risk

Parkinson's disease is the second most common neurodegenerative disorder, affecting 1–2% of the population over 65 and approximately 4% over 85. It is characterized by progressive motor symptoms (tremor, rigidity, bradykinesia), cognitive changes, and psychiatric features. Approximately 5–10% of PD cases have a clearly monogenic basis — caused by pathogenic variants in single genes with high penetrance. LRRK2 gain-of-function variants, most commonly G2019S, cause the most common monogenic form with age-related penetrance (~30% by age 80). SNCA variants (point mutations and gene multiplications) cause rare, aggressive early-onset disease. GBA variants are the most common genetic risk factor overall, present in 5–20% of PD patients depending on ethnicity (19.6% in Ashkenazi Jewish populations vs. ~5% baseline).

Approximately 25% of overall Parkinson's disease risk is attributed to genetic variation, though most cases are sporadic with complex polygenic contributions. The genetic landscape is heterogeneous, with over 90 GWAS loci identified contributing to disease susceptibility. The three major genes — LRRK2, SNCA, and GBA — converge on the α-synuclein-lysosomal axis. LRRK2 regulates autophagy and immune signaling; SNCA encodes α-synuclein (the primary component of Lewy bodies); GBA loss-of-function impairs lysosomal degradation of α-synuclein.

Understanding your Parkinson's genetic status has transformed clinical implications: monogenic findings like LRRK2 variants qualify you for disease-modifying LRRK2 kinase inhibitor trials (DNL201, BIIB122) — among the most promising precision medicine advances in neurodegeneration. GBA variant findings enable eligibility for substrate reduction therapy trials. For all genetic findings, cascade testing of family members, enrollment in longitudinal biomarker studies, and presymptomatic screening become possible. Parkinson's genetics is rapidly transitioning from academic interest to clinical actionability with real treatment options.

Gene locus
LRRK2 (12q12), SNCA (4q22.1), GBA (1q22)

Standard PD panels test limited genes. Over 25% of genetic PD risk comes from loci panels don't capture.

LRRK2-only testing misses GBA variants and polygenic risk

LRRK2-focused testing, commonly offered for Parkinson's disease, misses GBA variants, SNCA gene dosage changes, recessive PD genes (PARK2, PINK1, DJ-1), and the broader polygenic risk landscape. GBA testing is complicated by a highly homologous pseudogene (GBAP1) that can cause sequencing misalignment and false results. SNCA gene duplication and triplication require separate copy number analysis not always included in panels. Panels cannot capture the approximately 90 GWAS loci that collectively contribute to polygenic Parkinson's risk. Whole genome sequencing with proper depth and bioinformatic resolution captures all monogenic PD genes, GBA with pseudogene distinction, SNCA dosage, and genome-wide risk loci for comprehensive risk assessment.

Genetic findings now unlock disease-modifying trials and precision therapies

A LRRK2 gain-of-function variant qualifies you for LRRK2-targeted kinase inhibitor clinical trials (DNL201, BIIB122/denali) — potentially disease-modifying approaches that represent a genuine paradigm shift in neurodegeneration treatment. GBA loss-of-function findings enable eligibility for substrate reduction therapy trials and venglustat studies, with aggressive management of any Gaucher manifestations and awareness of faster motor and cognitive decline trajectories. SNCA variants qualify for gene-specific antisense oligonucleotide trials in development. For all genetic findings, enrollment in longitudinal biomarker studies (PPMI) enables presymptomatic progression tracking and trial readiness.

One test. A lifetime of answers.

One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.

From $449

Ships within 48 hours · Results in 6–8 weeks